Clinical trials: Antipsychotic
Healthy
The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals
The primary aim of this study is to investigate antipsychotic drug effects on healthy brain metabolism.
- Trial name
- NCT02536846
- Testing
- Olanzapine
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Dost Ongur
Schizophrenia
Safety and Efficacy of Cariprazine in Schizophrenia
The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.
- Trial name
- NCT01104779
- Testing
- Cariprazine
- Where
- 41 sites in United States, Colombia and 2 more
- Volunteers
- 446 people
- Sponsor
- Forest Laboratories
Psychosis, Remission
Guided Dose Reduction of Antipsychotic in Patients With Psychosis in Remitted States
A 2-year prospective observational study comparing a group of patients in remitted states of psychosis undergoing guided antipsychotic dose reduction to a similar group of patients under maintenance antipsychotic treatment with…
- Trial name
- GDR (NCT03248180)
- Where
- Taiwan
- Volunteers
- 160 people
- Sponsor
- National Taiwan University Hospital
Schizophrenia; Psychosis, Schizo Affective Disorder
Adapted Physical Activity Program for Patients Undergoing Antipsychotic Treatment of a First Episode of Psychosis
The purpose of this PILOT feasibility study is to verify the acceptability, feasibility, and compliance to the DYNAMO-PSY program among young adults treated with antipsychotics for a first episode of psychosis (FEP).
- Conditions
- Schizophrenia; Psychosis, Schizo Affective Disorder, First Episode Psychosis (FEP)
- Trial name
- DYNAMO-PSY (NCT06643871)
- Testing
- Adapted physical activity program involving connected bikes
- Volunteers
- 40 people
- Sponsor
- Centre Hospitalier St Anne
Schizophrenia, Psychotic Disorders
A Patient-Centered Approach to Improve Screening for Side Effects of Second Generation Antipsychotics (SGAs)
The purpose of this study is to determine if individuals with serious mental illnesses exposed to a patient-centered computerized tool versus printed educational materials have higher rates of screening for the metabolic side…
- Trial name
- NCT00677898
- Testing
- Patient-centered computerized tool, Written educational materials
- Where
- United States
- Volunteers
- 239 people
- Sponsor
- US Department of Veterans Affairs
Bipolar Disorder
Side Effect Study of Antipsychotic Medicines to Treat Childhood Bipolar Disorder
The purpose of this study is to learn more about weight gain and related side effects when children are treated with antipsychotic medicine for mood disorders.
- Trial name
- PAMS (NCT00746252)
- Testing
- risperidone, aripiprazole
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Maryland, Baltimore
Tobacco Dependence, Schizophrenia
The Pharmacogenetic Study , Readiness to Change, and Pharmacological Intervention for Smoking Cessation in Schizophrenia
Cigarette smoking represents a major health problem for patients suffering from schizophrenia. Compared to the general population, schizophrenic patients are significantly more likely to be addicted to nicotine.
- Trial name
- PSIAARP (NCT00495352)
- Testing
- Hihg-doseNRT, Low-dose NRT, bupropion
- Where
- Taiwan
- Volunteers
- 360 people
- Sponsor
- Yu-Li Hospital
Schizophrenia
Efficacy and Functional Recovery After Switching From Paliperidone Palmitate Injection to Oral Antipsychotics in Schizophrenia
To evaluate the efficacy of Paliperidone Palmitate Injection in replacing oral antipsychotics for the treatment of schizophrenia and its impact on social function
- Trial name
- NCT07075237
- Testing
- Paliperidone Palmitate Injection (PP1M)
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu Province Nanjing Brain Hospital
Schizophrenia
Observational Study to Evaluate Efficacy and Remission Status for Schizophrenia Patients Under Atypical Treatment
The objective of this study is to evaluate under routine clinical setting the efficacy and remission status from treatment of 2nd-generation antipsychotic in patients who is upon acute episode or not achieving remission under…
- Trial name
- QTP NIS (NCT00809731)
- Where
- 17 sites in Taiwan
- Volunteers
- 490 people
- Sponsor
- AstraZeneca
Colon Cancer Stage III
Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer
chlorpromazine displays a series of remarkable bio-molecular effects in cancer cells, as inhibition of cell growth, nuclear aberrations, inhibition of the phosphoinositide 3-kinase/mammilian target of rapamycin (PI3K/mTOR) axis…
- Trial name
- NCT05433402
- Testing
- ChlorproMAZINE 50 MG, Control
- Where
- Egypt
- Sponsor
- Sadat City University
Schizophrenia
Safety and Efficacy of Zicronapine in Patients With Schizophrenia
To assess the effect of zicronapine versus risperidone on metabolic parameters comprising body weight, body mass index (BMI), waist circumference, levels of fasting blood lipids and glucose during 6 months of treatment.
- Trial name
- NCT01295372
- Testing
- Zicronapine, Risperidone
- Where
- 24 sites in Czechia, Estonia and 3 more
- Volunteers
- 160 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia, Schizoaffective
The Consta Club: A Demonstration Project for Setting up a Consta Club in a Community Mental Health Center
This study will establish a bi-weekly Consta Club. Participants will begin taking Risperdal Consta after being recommended by their treating physician.
- Trial name
- NCT00845572
- Testing
- Consta Club
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Schizophrenia
Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia
This study will compare the safety and effectiveness of three different antipsychotic medications, as well as the use of other medications to limit treatment side effects, in adults with schizophrenia.
- Trial name
- COATS (NCT00802100)
- Testing
- Olanzapine, Perphenazine, Aripiprazole
- Where
- 13 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia
Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)
This study is a sequential multiple-assignment randomized trial (RCT) of antipsychotic medication treatment in first-episode schizophrenia patients in the real-world settings.Through analysis of treatment efficacy rate and…
- Trial name
- NCT03510325
- Testing
- Phase 1: Olanzapine, Phase 1: Risperidone, Phase 1: Amisulpride
- Where
- 7 sites in China
- Volunteers
- 762 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia
Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics
This is a randomized, double-blind, placebo-controlled, sequential cohort, ascending oral dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of EVP-6308 administered for 14 days in subjects with…
- Trial name
- NCT02037074
- Testing
- Drug: EVP-6308
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- FORUM Pharmaceuticals Inc
Schizophrenia
Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone
The primary purpose of this study is to determine whether a combination of ACP-103 (the study medication) with either haloperidol or risperidone will show antipsychotic efficacy and that it is safe and well tolerated.
- Trial name
- NCT00361166
- Testing
- ACP-103
- Where
- 17 sites in United States, Brazil
- Volunteers
- 400 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Urinary Tract Infections (UTIs), Urinary Tract Infection, Recurrent
Effects of Pomegranate Seed Oil Supplementation in Patients With Advanced Dementia
The goal of this clinical study is to learn if Pomegranate Seed Oil supplementation works to combat urinary tract infections, recurrenturinary tract infections, or pneumonia and contributes to the tapering or discontinuation of…
- Conditions
- Urinary Tract Infections (UTIs), Urinary Tract Infection, Recurrent, Antipsychotics Discontinuation, Antipsychotics Tapering
- Trial name
- NCT07432763
- Testing
- Pomegranate Seed Oil Supplementation in Palliative Care Patients with Advanced Dementia, Care-as-usual
- Where
- Greece
- Volunteers
- 18 people
- Sponsor
- Panhellenic Federation of Alzheimer's Disease and Related Disorders
Schizophrenia
Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia
AVE1625 is a new potent and selective cannabinoid 1 (CB1) antagonist in clinical development for the treatment of cognitive impairment in patients diagnosed with schizophrenia.
- Trial name
- CONNECT (NCT00439634)
- Testing
- AVE1625
- Where
- 2 sites in United States, Canada
- Volunteers
- 873 people
- Sponsor
- Sanofi
Bipolar Disorders
A NIS Evaluating the Treatment Patterns of Atypical Antipsychotics in Patients Diagnosed With Bipolar I or II Disorder
The purpose of this NIS is to obtain data on how AAPs are used in DSM-IV-TR Bipolar I and II Disorder, in the course of a major depressive episode.
- Trial name
- HARMONY (NCT00888264)
- Where
- 45 sites in Belgium
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
Patient With Schizophrenia Spectrum Disorder, NLM Classification WM 203, Psychology:Schizophrenic Psychology
Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach
The objective of this study is to respond to frequent requests from patients who wish to reduce or even stop their antipsychotic treatment once they have achieved clinical stability.
- Conditions
- Patient With Schizophrenia Spectrum Disorder, NLM Classification WM 203, Psychology:Schizophrenic Psychology, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- DREAMS-Phen (NCT07152184)
- Testing
- Use of antipsychotic treatment with marketing authorization at doses lower than those recommended: - Olanzapine - Zuclopenthixol - Risperidone - Pipotiazine palmitate / Pipotiazine - Quetiapine - Flup
- Volunteers
- 288 people
- Sponsor
- University Hospital, Strasbourg, France